Genotype-Based Ancestral Background Consistently Predicts Efficacy and Side Effects across Treatments in CATIE and STAR*D

被引:7
作者
Adkins, Daniel E. [1 ]
Souza, Renan P. [1 ]
Aberg, Karolina [1 ]
Clark, Shaunna L. [1 ]
McClay, Joseph L. [1 ]
Sullivan, Patrick F. [2 ,3 ,4 ,5 ]
van den Oord, Edwin J. C. G. [1 ]
机构
[1] Virginia Commonwealth Univ, Med Coll Virginia, Sch Pharm, Ctr Biomarker Res & Personalized Med, Richmond, VA 23298 USA
[2] Univ N Carolina, Dept Genet, Chapel Hill, NC USA
[3] Univ N Carolina, Dept Psychiat, Chapel Hill, NC USA
[4] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA
[5] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden
关键词
NUCLEOTIDE-POLYMORPHISM PANEL; FALSE DISCOVERY RATE; GENOMEWIDE ASSOCIATION; SCHIZOPHRENIA; OUTCOMES; RACE; CARE;
D O I
10.1371/journal.pone.0055239
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
070301 [无机化学]; 070403 [天体物理学]; 070507 [自然资源与国土空间规划学]; 090105 [作物生产系统与生态工程];
摘要
Only a subset of patients will typically respond to any given prescribed drug. The time it takes clinicians to declare a treatment ineffective leaves the patient in an impaired state and at unnecessary risk for adverse drug effects. Thus, diagnostic tests robustly predicting the most effective and safe medication for each patient prior to starting pharmacotherapy would have tremendous clinical value. In this article, we evaluated the use of genetic markers to estimate ancestry as a predictive component of such diagnostic tests. We first estimated each patient's unique mosaic of ancestral backgrounds using genome-wide SNP data collected in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) (n = 765) and the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) (n = 1892). Next, we performed multiple regression analyses to estimate the predictive power of these ancestral dimensions. For 136/89 treatment-outcome combinations tested in CATIE/STAR*D, results indicated 1.67/1.84 times higher median test statistics than expected under the null hypothesis assuming no predictive power (p<0.01, both samples). Thus, ancestry showed robust and pervasive correlations with drug efficacy and side effects in both CATIE and STAR*D. Comparison of the marginal predictive power of MDS ancestral dimensions and self-reported race indicated significant improvements to model fit with the inclusion of MDS dimensions, but mixed evidence for self-reported race. Knowledge of each patient's unique mosaic of ancestral backgrounds provides a potent immediate starting point for developing algorithms identifying the most effective and safe medication for a wide variety of drug-treatment response combinations. As relatively few new psychiatric drugs are currently under development, such personalized medicine offers a promising approach toward optimizing pharmacotherapy for psychiatric conditions.
引用
收藏
页数:9
相关论文
共 43 条
[1]
Aberg K., 2010, Pharmacogenomics Journal
[2]
Genomewide Association Study of Movement-Related Adverse Antipsychotic Effects [J].
Aberg, Karolina ;
Adkins, Daniel E. ;
Bukszar, Jozsef ;
Webb, Bradley T. ;
Caroff, Stanley N. ;
Miller, Del D. ;
Sebat, Jonathan ;
Stroup, Scott ;
Fanous, Ayman H. ;
Vladimirov, Vladimir I. ;
McClay, Joseph L. ;
Lieberman, Jeffrey A. ;
Sullivan, Patrick F. ;
van den Oord, Edwin J. C. G. .
BIOLOGICAL PSYCHIATRY, 2010, 67 (03) :279-282
[3]
Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D [J].
Adkins, D. E. ;
Clark, S. L. ;
Aberg, K. ;
Hettema, J. M. ;
Bukszar, J. ;
McClay, J. L. ;
Souza, R. P. ;
van den Oord, E. J. C. G. .
TRANSLATIONAL PSYCHIATRY, 2012, 2 :e129-e129
[4]
Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs [J].
Adkins, D. E. ;
Aberg, K. ;
McClay, J. L. ;
Bukszar, J. ;
Zhao, Z. ;
Jia, P. ;
Stroup, T. S. ;
Perkins, D. ;
McEvoy, J. P. ;
Lieberman, J. A. ;
Sullivan, P. F. ;
van den Oord, E. J. C. G. .
MOLECULAR PSYCHIATRY, 2011, 16 (03) :321-332
[5]
SNP-based analysis of neuroactive ligand-receptor interaction pathways implicates PGE2 as a novel mediator of antipsychotic treatment response: Data from the CATIE study [J].
Adkins, Daniel E. ;
Khachane, Amit N. ;
McClay, Joseph L. ;
Aberg, Karolina ;
Bukszar, Jozsef ;
Sullivan, Patrick F. ;
van den Oord, Edwin J. C. G. .
SCHIZOPHRENIA RESEARCH, 2012, 135 (1-3) :200-201
[6]
Adkins Daniel E, 2010, Biol Psychiatry, V68, pe25, DOI 10.1016/j.biopsych.2010.05.018
[7]
Data quality control in genetic case-control association studies [J].
Anderson, Carl A. ;
Pettersson, Fredrik H. ;
Clarke, Geraldine M. ;
Cardon, Lon R. ;
Morris, Andrew P. ;
Zondervan, Krina T. .
NATURE PROTOCOLS, 2010, 5 (09) :1564-1573
[8]
Clinical assessment incorporating a personal genome [J].
Ashley, Euan A. ;
Butte, Atul J. ;
Wheeler, Matthew T. ;
Chen, Rong ;
Klein, Teri E. ;
Dewey, Frederick E. ;
Dudley, Joel T. ;
Ormond, Kelly E. ;
Pavlovic, Aleksandra ;
Morgan, Alexander A. ;
Pushkarev, Dmitry ;
Neff, Norma F. ;
Hudgins, Louanne ;
Gong, Li ;
Hodges, Laura M. ;
Berlin, Dorit S. ;
Thorn, Caroline F. ;
Sangkuhl, Katrin ;
Hebert, Joan M. ;
Woon, Mark ;
Sagreiya, Hersh ;
Whaley, Ryan ;
Knowles, Joshua W. ;
Chou, Michael F. ;
Thakuria, Joseph V. ;
Rosenbaum, Abraham M. ;
Zaranek, Alexander Wait ;
Church, George M. ;
Greely, Henry T. ;
Quake, Stephen R. ;
Altman, Russ B. .
LANCET, 2010, 375 (9725) :1525-1535
[9]
CONTROLLING THE FALSE DISCOVERY RATE - A PRACTICAL AND POWERFUL APPROACH TO MULTIPLE TESTING [J].
BENJAMINI, Y ;
HOCHBERG, Y .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY, 1995, 57 (01) :289-300
[10]
Clinically responsible genetic testing in neuropsychiatric patients: A bridge too far and too soon [J].
Braff, David L. ;
Freedman, Robert .
AMERICAN JOURNAL OF PSYCHIATRY, 2008, 165 (08) :952-955